Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Henan Lingrui Pharmaceutical Co's EV-to-EBIT or its related term are showing as below:
SHSE:600285'
s EV-to-EBIT Range Over the Past 10 Years
Min: 10.08 Med: 13.93 Max: 33.83
Current: 11.72
During the past 13 years, the highest EV-to-EBIT of Henan Lingrui Pharmaceutical Co was 33.83. The lowest was 10.08. And the median was 13.93.
SHSE:600285's EV-to-EBIT is ranked better than 63.64% of 682
companies
in the Drug Manufacturers industry
Industry Median: 15.985
vs SHSE:600285: 11.72
Henan Lingrui Pharmaceutical Co (SHSE:600285) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Henan Lingrui Pharmaceutical Co's Enterprise Value for the quarter that ended in Jun. 2026 was ¥10,521 Mil.
Henan Lingrui Pharmaceutical Co's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥909 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Henan Lingrui Pharmaceutical Co EV-to-EBIT Related Terms
Henan Lingrui Pharmaceutical Co EV-to-EBIT Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Henan Lingrui Pharmaceutical Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Henan Lingrui Pharmaceutical Co EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Henan Lingrui Pharmaceutical Co's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Henan Lingrui Pharmaceutical Co's EV-to-EBIT falls into.
Henan Lingrui Pharmaceutical Co's current Enterprise Value is ¥10,652 Mil.
Henan Lingrui Pharmaceutical Co's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥909 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Henan Lingrui Pharmaceutical Co (SHSE:600285) has a EV-to-EBIT of 11.72 as of Sep. 05, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Henan Lingrui Pharmaceutical Co and its competitors. This is 16% below median its historical median of 13.93. Over the past decade, Henan Lingrui Pharmaceutical Co's EV-to-EBIT has ranged from 10.08 to 33.83. According to the industry distribution chart, Henan Lingrui Pharmaceutical Co ranks #248 out of 682 companies in the Drug Manufacturers industry, placing it in the top 36.4%.
Is Henan Lingrui Pharmaceutical Co's EV-to-EBIT too high?
Henan Lingrui Pharmaceutical Co's current EV-to-EBIT of 11.72 is 16% below median its 10-year median of 13.93. Over the past 10 years, this metric has ranged from a low of 10.08 to a high of 33.83. The Drug Manufacturers industry median EV-to-EBIT is 15.99. Henan Lingrui Pharmaceutical Co's value of 11.72 is 26.7% below this industry median. Based on the distribution chart, Henan Lingrui Pharmaceutical Co ranks #248 out of 682 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Henan Lingrui Pharmaceutical Co has a GF Score™ of 95/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Henan Lingrui Pharmaceutical Co's EV-to-EBIT compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Henan Lingrui Pharmaceutical Co ranks #248 out of 682 companies for EV-to-EBIT. This puts Henan Lingrui Pharmaceutical Co in the upper half of its industry. The industry median EV-to-EBIT is 15.99. Henan Lingrui Pharmaceutical Co's value of 11.72 is 26.7% below this benchmark. Historically, Henan Lingrui Pharmaceutical Co's own EV-to-EBIT has ranged from 10.08 to 33.83 over the past decade. While the company's 10-year median is 13.93 vs. the industry median of 15.99, Henan Lingrui Pharmaceutical Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 15.99, based on 682 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Henan Lingrui Pharmaceutical Co's current EV-to-EBIT of 11.72 is 26.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Henan Lingrui Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 15.99 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Henan Lingrui Pharmaceutical Co's current EV-to-EBIT is 11.72, which is 16% below median its own 10-year median of 13.93. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Henan Lingrui Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Henan Lingrui Pharmaceutical Co (SHSE:600285) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥23.78, compared to a current price of ¥19.61 — trading 17.5% below its estimated fair value. The current EV-to-EBIT is 11.72, which is 16% below median its 10-year median of 13.93 and 26.7% below the Drug Manufacturers industry median of 15.99. Henan Lingrui Pharmaceutical Co's overall GF Score™ is 95/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Henan Lingrui Pharmaceutical Co (SHSE:600285), the current EV-to-EBIT is 11.72 as of Sep. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Henan Lingrui Pharmaceutical Co (SHSE:600285) Overvalued in 2026?
Based on GuruFocus' analysis, Henan Lingrui Pharmaceutical Co stock appears to be undervalued.
The current stock price of ¥19.61 is trading 17.5% below its estimated GF Value™ of ¥23.78.
GuruFocus considers Henan Lingrui Pharmaceutical Co to be Modestly Undervalued.
Key valuation signals for SHSE:600285:
EV-to-EBIT: 11.72 (16% below median its 10-year median of 13.93)
GF Value™: ¥23.78 vs. price of ¥19.61 (17.5% below fair value)
Industry Position: 26.7% below the Drug Manufacturers median (#248 of 682)
No single metric tells the full story. See the SHSE:600285 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Henan Lingrui Pharmaceutical Co Ltd is a Chinese company engaged in the development, production, and distribution of pharmaceuticals. The Company's products include tablets, capsules, injections and other medicines.
95GF Score
Get the complete analysis for SHSE:600285
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600285 has been successfully added to your 
